GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
‘Discipline, management and political leadership’ must guide decisions – Tony Zahra
No matter what size a country is, no country can pursue every opportunity, Tony Zahra says.
How a witty reply to Jack Whitehall became one of Malta’s most memorable marketing moments
Malta's national airline's casual tweet brought Jack Whitehall to Malta.
Ronald Sultana appointed CEO of Gozo Channel
Marlene Cini has also been appointed Gozo Channel Chairperson.
Malta’s Central Bank Governor urges ECB caution as oil prices ease inflation pressures
Speaking to Reuters on the sidelines of the ECB Forum on Central Banking, he said that, with price pressures continuing ...
